ISRVF:OTC-iShares Public Limited Company - iShares MSCI Japan USD Hedged UCITS ETF (Acc) (USD)

ETF | Others |

Last Closing

USD 80.29

Change

0.00 (0.00)%

Market Cap

N/A

Volume

124.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-17 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CSTNL iShares VII Public Limited Com..

N/A

USD 32.85B
ZKBGF ZKB Gold ETF

N/A

USD 8.96B
TOETF Tosei Corporation

N/A

USD 7.70B
EFMSF ETFS Metal Securities Limited ..

N/A

USD 7.39B
SSEEF SSgA SPDR ETFs Europe I Public..

N/A

USD 2.95B
IFXAF iShares Asia Trust - iShares F..

N/A

USD 2.94B
ZKBHF ZKB Gold ETF

N/A

USD 2.93B
GDRPF Golden Resources Development I..

N/A

USD 2.70B
ISRPF iShares Public Limited Company..

N/A

USD 2.22B
TRUBF TRUBF

N/A

USD 1.22B

ETFs Containing ISRVF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 34.45% 92% A 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.45% 92% A 81% B-
Trailing 12 Months  
Capital Gain 39.11% 92% A 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.11% 92% A 82% B
Trailing 5 Years  
Capital Gain 132.86% 97% N/A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 132.86% 97% N/A 89% A-
Average Annual (5 Year Horizon)  
Capital Gain 17.71% 84% B 64% D
Dividend Return 17.71% 84% B 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.79% 54% F 91% A-
Risk Adjusted Return 112.13% 100% F 99% N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike